JPWO2020058285A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020058285A5 JPWO2020058285A5 JP2021514551A JP2021514551A JPWO2020058285A5 JP WO2020058285 A5 JPWO2020058285 A5 JP WO2020058285A5 JP 2021514551 A JP2021514551 A JP 2021514551A JP 2021514551 A JP2021514551 A JP 2021514551A JP WO2020058285 A5 JPWO2020058285 A5 JP WO2020058285A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- peptide
- fragment
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 56
- 239000012634 fragment Substances 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 18
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 17
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 17
- 108091008874 T cell receptors Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000013604 expression vector Substances 0.000 claims 8
- 108020001507 fusion proteins Proteins 0.000 claims 8
- 102000037865 fusion proteins Human genes 0.000 claims 8
- 108091023037 Aptamer Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 238000002659 cell therapy Methods 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 201000010175 gallbladder cancer Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000009257 reactivity Effects 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732300P | 2018-09-17 | 2018-09-17 | |
| DE102018122623 | 2018-09-17 | ||
| US62/732,300 | 2018-09-17 | ||
| DE102018122623.3 | 2018-09-17 | ||
| PCT/EP2019/074898 WO2020058285A1 (en) | 2018-09-17 | 2019-09-17 | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502015A JP2022502015A (ja) | 2022-01-11 |
| JP2022502015A5 JP2022502015A5 (https=) | 2022-09-29 |
| JPWO2020058285A5 true JPWO2020058285A5 (https=) | 2022-09-29 |
Family
ID=67999633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514551A Ceased JP2022502015A (ja) | 2018-09-17 | 2019-09-17 | がんに対する免疫療法で使用するためのｂ＊４４拘束性ペプチドおよび関連方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (18) | US11945850B2 (https=) |
| EP (1) | EP3853243A1 (https=) |
| JP (1) | JP2022502015A (https=) |
| KR (1) | KR20210061340A (https=) |
| CN (1) | CN112789285A (https=) |
| AU (1) | AU2019344565B2 (https=) |
| BR (1) | BR112021004170A2 (https=) |
| CA (1) | CA3108578A1 (https=) |
| CL (1) | CL2021000649A1 (https=) |
| CO (1) | CO2021004270A2 (https=) |
| CR (1) | CR20210140A (https=) |
| IL (2) | IL309716A (https=) |
| MA (1) | MA53641A (https=) |
| MX (1) | MX2021003067A (https=) |
| PE (1) | PE20211642A1 (https=) |
| PH (1) | PH12021550346A1 (https=) |
| SG (1) | SG11202101924QA (https=) |
| TW (1) | TW202028224A (https=) |
| WO (1) | WO2020058285A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| EA201991444A1 (ru) * | 2017-01-27 | 2019-12-30 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака |
| IL299051A (en) | 2017-01-27 | 2023-02-01 | Immatics Biotechnologies Gmbh | New peptides and their combinations for immunotherapy against ovarian cancer and other cancers |
| CR20200059A (es) | 2017-07-07 | 2020-06-01 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres |
| US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| EP4091627A1 (en) * | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| WO2024178334A1 (en) * | 2023-02-24 | 2024-08-29 | The Children's Hospital Of Philadelphia | Improved phox2b pc-car generation based on structure and saturation mutagenesis |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IL59007A (en) | 1978-12-22 | 1983-11-30 | Biogen Nv | Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US5977300A (en) | 1994-06-03 | 1999-11-02 | Ludwig Institute Of Cancer Research | Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof |
| ES2203782T3 (es) | 1996-01-17 | 2004-04-16 | Imperial College Innovations Limited | Inmunoterapia que utiliza linfocitos t citotoxicos (ctl). |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1266221A1 (en) | 2000-01-20 | 2002-12-18 | Ludwig Institute For Cancer Research | Mage antigenic peptides which bind hla-b35 and hla-b44 |
| DE60142475D1 (de) | 2000-03-27 | 2010-08-12 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| US20030171275A1 (en) | 2000-12-20 | 2003-09-11 | Baughn Mariah R. | Transporters and ion channels |
| US20030087245A1 (en) | 2001-01-24 | 2003-05-08 | Eos Biotechnology, Inc. | Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer |
| WO2003004989A2 (en) | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| DE60327795D1 (de) | 2002-11-09 | 2009-07-09 | Immunocore Ltd | T zell rezeptor "display" |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7348007B2 (en) | 2004-02-09 | 2008-03-25 | Ludwig Institute For Cancer Research | Mage C2 antigenic peptides and uses thereof |
| US7883858B2 (en) | 2005-01-27 | 2011-02-08 | Institute For Systems Biology | Methods for identifying and monitoring drug side effects |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| AU2006308863A1 (en) | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | A polypeptide complex of TRPM8 and calmodulin and its uses thereof |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| BR112012029066A2 (pt) | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| US20140170168A1 (en) | 2010-10-26 | 2014-06-19 | Yoram Reiter | Antibodies which bind soluble t-cell receptor ligands |
| WO2012094744A1 (en) | 2011-01-11 | 2012-07-19 | University Health Network | Prognostic signature for oral squamous cell carcinoma |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| US12540318B2 (en) | 2012-11-08 | 2026-02-03 | Roche Diagnostics Operations, Inc. | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| CN108135973B (zh) | 2015-05-19 | 2021-10-19 | 拉·约拉过敏反应及免疫医学研究所 | 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途 |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201520541D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| DK3515476T3 (da) * | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| MA47678A (fr) * | 2017-03-03 | 2021-05-26 | Treos Bio Ltd | Plateforme personnalisée d'identification de peptide immunogène |
| US11427614B2 (en) | 2017-04-10 | 2022-08-30 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| TW201841937A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於白血病和其他癌症免疫治療的新穎肽和肽組合物 |
| US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
-
2019
- 2019-09-16 US US16/571,982 patent/US11945850B2/en active Active
- 2019-09-16 TW TW108133170A patent/TW202028224A/zh unknown
- 2019-09-17 MX MX2021003067A patent/MX2021003067A/es unknown
- 2019-09-17 MA MA053641A patent/MA53641A/fr unknown
- 2019-09-17 AU AU2019344565A patent/AU2019344565B2/en not_active Ceased
- 2019-09-17 CN CN201980060418.2A patent/CN112789285A/zh active Pending
- 2019-09-17 IL IL309716A patent/IL309716A/en unknown
- 2019-09-17 CA CA3108578A patent/CA3108578A1/en active Pending
- 2019-09-17 PE PE2021000318A patent/PE20211642A1/es unknown
- 2019-09-17 BR BR112021004170-2A patent/BR112021004170A2/pt not_active IP Right Cessation
- 2019-09-17 SG SG11202101924QA patent/SG11202101924QA/en unknown
- 2019-09-17 JP JP2021514551A patent/JP2022502015A/ja not_active Ceased
- 2019-09-17 WO PCT/EP2019/074898 patent/WO2020058285A1/en not_active Ceased
- 2019-09-17 CR CR20210140A patent/CR20210140A/es unknown
- 2019-09-17 KR KR1020217006532A patent/KR20210061340A/ko not_active Ceased
- 2019-09-17 EP EP19773029.4A patent/EP3853243A1/en not_active Withdrawn
-
2020
- 2020-06-30 US US16/916,432 patent/US20200339644A1/en not_active Abandoned
- 2020-06-30 US US16/916,450 patent/US10899811B2/en not_active Expired - Fee Related
- 2020-06-30 US US16/916,438 patent/US11111281B2/en not_active Expired - Fee Related
- 2020-06-30 US US16/916,443 patent/US11208448B2/en not_active Expired - Fee Related
- 2020-06-30 US US16/916,447 patent/US10899810B2/en not_active Expired - Fee Related
- 2020-12-10 US US17/117,964 patent/US11014972B2/en not_active Expired - Fee Related
-
2021
- 2021-02-18 PH PH12021550346A patent/PH12021550346A1/en unknown
- 2021-03-17 IL IL281605A patent/IL281605A/en unknown
- 2021-03-17 CL CL2021000649A patent/CL2021000649A1/es unknown
- 2021-04-07 CO CONC2021/0004270A patent/CO2021004270A2/es unknown
- 2021-04-13 US US17/229,610 patent/US11117941B2/en active Active
- 2021-05-07 US US17/314,397 patent/US11155590B2/en active Active
- 2021-09-17 US US17/478,041 patent/US12065471B2/en active Active
-
2022
- 2022-08-12 US US17/886,973 patent/US20230002462A1/en not_active Abandoned
- 2022-08-26 US US17/896,923 patent/US11629177B2/en active Active
- 2022-09-02 US US17/929,465 patent/US11667685B2/en active Active
- 2022-09-09 US US17/930,969 patent/US11680089B2/en active Active
-
2023
- 2023-02-16 US US18/170,154 patent/US12162917B2/en active Active
- 2023-03-24 US US18/189,443 patent/US20230287071A1/en not_active Abandoned
- 2023-03-24 US US18/189,448 patent/US20230265140A1/en not_active Abandoned
- 2023-03-30 US US18/192,715 patent/US20230382963A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024041841A5 (https=) | ||
| JP2024099580A5 (https=) | ||
| JP2021535900A5 (https=) | ||
| JP2022502015A5 (https=) | ||
| JP2020516681A5 (https=) | ||
| JP2021168652A5 (https=) | ||
| JP2019511214A5 (https=) | ||
| JP6639233B2 (ja) | Ｍａｇｅ−ａ１を認識する高結合活性結合分子 | |
| JP2020198875A5 (https=) | ||
| JP2021101700A5 (https=) | ||
| JP2019502360A5 (https=) | ||
| JP2021528046A5 (https=) | ||
| JP2021514178A5 (https=) | ||
| JP2018510628A5 (https=) | ||
| JP2018529320A5 (https=) | ||
| JP2019516663A5 (https=) | ||
| JP2019506838A5 (https=) | ||
| JP2019510465A5 (https=) | ||
| JP2018509135A5 (https=) | ||
| JP2018518937A5 (https=) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| US20070237771A1 (en) | Multicomponent conjugates which bind to target molecules and stimulate T cell lysis | |
| JP2021522779A5 (https=) | ||
| JP2019515653A5 (https=) | ||
| JP2020530759A5 (https=) |